LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

NCT00711594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BIBW 2992 MA2 40mg/day
DRUG: BIBW 2992 MA2 50mg/day
DRUG: BIBW 2992 MA2 20mg/day
DRUG: BIBW 2992 QD

Sponsor

Boehringer Ingelheim